|
Dr. Hoekstra joined Nanogen as head of Business Development through the Epoch merger. He was Vice President of Corporate Development for Epoch from March 2001 and had responsibility for business development, product development and product management, sales, marketing and M & A activity. Prior to Epoch, he was Chief Science Officer and General Manager of Qbiogene, where he had overall responsibility for U.S. operations and worldwide. Dr. Hoekstra has also held Research and Development positions at Signal Pharmaceuticals and Icos Corporation. He has been co-founder and Scientific Advisory Board member for Ceptyr, Cascade Oncogenics and MycoGenetics. Dr. Hoekstra has previously served as Assistant Professor, Molecular Biology and Virology Labs at the Salk Institute and is currently an Adjunct Professor of Pharmacology at the University of California, San Diego. He received a Ph.D. from Loyola University's Stritch School of Medicine and a B.Sc. from the University of British Columbia. | 